LGND · ISSUER CIK 886163
LIGAND PHARMACEUTICALS INC
Between Aug 1, 2026 and Oct 29, 2026, 4 LIGAND PHARMACEUTICALS INC insiders reported $0.00 of open-market purchases and $16.1M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$16.1MInsider selling
−$16.1MNet open-market
Oct 6, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 202616:35 | Oct 2, 2026 | LGND | CLO & Secretary | S · Sell10b5-1 | $304.07 | −5,000 | 31,854 | -14% | −$1.5M | ||
| Oct 6, 202616:35 | Oct 2, 2026 | LGND | CLO & Secretary | M · Exercise10b5-1 | $52.27 | +340 | 36,854 | +1% | $18K | ||
| Sep 24, 202617:22 | Sep 22, 2026 | LGND | Director | F · Tax | $298.50 | −115 | 3,782 | -3% | $34K | ||
| Sep 14, 202616:59 | Sep 10, 2026 | LGND | Director | S · Sell | $285.00 | −1,200 | 3,897 | -24% | −$342K | ||
| Sep 8, 202618:34 | Sep 3, 2026 | LGND | CLO & Secretary | S · Sell10b5-1Late 5d | $286.09 | −5,000 | 36,514 | -12% | −$1.4M | ||
| Aug 14, 202617:05 | Aug 12, 2026 | LGND | Chief Financial Officer | S · Sell10b5-1 | $292.07 | −31,641 | 27,696 | -53% | −$9.2M | ||
| Aug 14, 202617:05 | Aug 12, 2026 | LGND | Chief Financial Officer | M · Exercise10b5-1 | $56.91 | +31,641 | 59,337 | +114% | $1.8M | ||
| Aug 14, 202617:04 | Aug 12, 2026 | LGND | Director | S · Sell | $292.81 | −7,138 | 3,981 | -64% | −$2.1M | ||
| Aug 14, 202617:04 | Aug 12, 2026 | LGND | Director | M · Exercise | $51.56 | +6,138 | 11,119 | +123% | $316K | ||
| Aug 4, 202618:42 | Aug 3, 2026 | LGND | CLO & Secretary | S · Sell10b5-1 | $288.99 | −5,000 | 41,514 | -11% | −$1.4M | ||
| Aug 4, 202618:42 | Aug 3, 2026 | LGND | CLO & Secretary | M · Exercise10b5-1 | $52.27 | +5,000 | 46,514 | +12% | $261K |